CRISPR Therapeutics
NEWS
It was another busy week for clinical trial updates and news. Here’s a look.
Despite promising Phase I data for its CRISPR-based allogeneic CAR-T therapy, CRISPR Therapeutics may have a safety issue to contend with.
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
As usual, it was a busy week for clinical trial updates. Here’s a look.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
JOBS
IN THE PRESS